Outcome of Non-Critical COVID-19 Patients with Early Hospitalization and Early Antiviral Treatment Outside the ICU
BaŞaran et al.
, Outcome of Non-Critical COVID-19 Patients with Early Hospitalization and Early Antiviral Treatment Outside the..
, Turk. J. Med. Sci., doi:10.3906/sag-2006-173
Observational study of 174 hospitalized patients in Turkey, median age 45.4, 23 treated with HCQ, 113 with HCQ+AZ, and 32 with regimens including favipiravir. 75% reduction in the median time to clinical improvement for HCQ+AZ vs. FAV, RR 0.25, p
<0.001. 83% reduction for HCQ. However, there was significant confounding by indication
There were no significant adverse events.
BaŞaran et al., 28 Jul 2020, prospective, Turkey, peer-reviewed, 18 authors.
Abstract: Turkish Journal of Medical Sciences
Turk J Med Sci
(2021) 51: 411-420
Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral
treatment outside the ICU
Nursel ÇALIK BAŞARAN *, Oğuz Abdullah UYAROĞLU , Gülçin TELLİ DİZMAN ,
Lale ÖZIŞIK , Taha Koray ŞAHİN , Zahit TAŞ , Ahmet Çağkan İNKAYA , Sevilay KARAHAN ,
Şehnaz ALP , Alpaslan ALP , Gökhan METAN , Pınar ZARAKOLU , Gülay SAİN GÜVEN ,
Şerife Gül ÖZ , Arzu TOPELİ , Ömrüm UZUN , Murat AKOVA , Serhat ÜNAL
Department of Internal Medicine, General Internal Medicine Division,
Faculty of Medicine, Hacettepe University, Ankara, Turkey
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey
Department of Biostatistics, Faculty of Medicine, Hacettepe University, Ankara, Turkey
Department of Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
Department of Internal Medicine, Intensive Care Division, Faculty of Medicine, ,Hacettepe University, Ankara, Turkey
Accepted/Published Online: 26.07.2021
Final Version: 30.04.2021
Background/aim: Despite the fact that the COVID-19 pandemic has been going on for over 5 months, there is yet to be a standard
management policy for all patients including those with mild-to-moderate cases. We evaluated the role of early hospitalization in
combination with early antiviral therapy with COVID-19 patients in a tertiary care university hospital.
Materials and methods: This was a prospective, observational, single-center study on probable/confirmed COVID-19 patients
hospitalized in a tertiary care hospital on COVID-19 wards between March 20 and April 30, 2020. The demographic, laboratory, and
clinical data were collected.
Results: We included 174 consecutive probable/confirmed COVID-19 adult patients hospitalized in the Internal Medicine wards of the
University Adult Hospital between March 20 and April 30, 2020. The median age was 45.5 (19–92) years and 91 patients (52.3%) were
male. One hundred and twenty (69%) were confirmed microbiologically, 41 (23.5%) were radiologically diagnosed, and 13 (7.5%) were
clinically suspected (negative microbiological and radiological findings compatible with COVID-19); 35 (20.1%) had mild, 107 (61.5%)
moderate disease, and 32 (18.4%) had severe pneumonia. Out of 171 cases, 130 (74.3%) showed pneumonia; 80 were typical, and 50
showed indeterminate infiltration for COVID-19. Patients were admitted within a median of 3 days (0-14 days) after symptoms appear.
The median duration of hospitalization was 4 days (0-28 days). In this case series, 13.2% patients were treated with hydroxychloroquine
alone, 64.9% with hydroxychloroquine plus azithromycin, and 18.4% with regimens including favipiravir. A total of 15 patients (8.5%)
were transferred to the ICU. Four patients died (2.2%).
Conclusion: In our series, 174 patients were admitted to the hospital wards for COVID-19, 69% were confirmed with PCR and/or antibody
test. At the time of admission, nearly one fifth of the patients had severe diseases. Of the patients, 95.4% received hydroxychloroquine
alone or in combination. The overall case fatality rate was 2.2%.
Key words: COVID-19, noncritical illness,..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.